Similarly, for pharmacologic treatment, we measured five to eight items: whether providers added, continued, switched, or stopped diabetes- (metformin, insulin, sulfonylurea, SGLT2i, GLP1 RA) and CV- (statin, antihypertensive) related drugs at least half the time. The gene discussed is INS; the disease is diabetes mellitus.